Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation
- 2,204 patients with paroxysmal atrial fibrillation
- 18 to 90 yrs old
Trial Design: Randomized, open label, parallel assignment
Intervention: left atrial ablation versus rate or rhythm control medical therapy
Primary Endpoint: Composite of total mortality, disabling stroke, serious bleeding, or cardiac arrest
Sponsors: Mao Clinic, NIH, NHLBI
Quality of Life Substudy
Daniel B. Mark, MD
Primary QOL Measures:
- Atrial Fibrillation Effect and Quality of Life (AFEQT) Scale
- Mayo AF-Specific Symptom Inventory (MAFSI)
Other QOL Measures:
- Duke Activity Status Index (DASI)
- Toronto Atrial Fibrillation Severity Score
- Stanford Presenteeism Scale (SPS-6)
- Work Productivity and Activity Impairment Questionnaire (WPAI)
CABANA: QUALITY OF LIFE STUDY
The specific aim of the Quality of Life substudy of the CABANA trial is to compare health-related quality of life for atrial fibrillation versus rate or rhythm medical therapy.
The CABANA trial is finished recruiting and follow-up data collection is ongoing.
See study website for more information.
Awaiting trial results.